Laboratory of Microbial Technology, Division of Applied Molecular Microbiology and Biomass Chemistry, Department of Bioscience and Biotechnology, Graduate School, Kyushu University, 6-10-1 Hakozaki, Higashi-ku, Fukuoka, 812-8581, Japan.
Appl Microbiol Biotechnol. 2012 Jan;93(2):671-8. doi: 10.1007/s00253-011-3563-1. Epub 2011 Sep 9.
Nukacin D13E (D13E) is a variant of type-A(II) lantibiotic nukacin ISK-1 produced by Staphylococcus warneri ISK-1. D13E exhibited a twofold higher specific antimicrobial activity than nukacin ISK-1 against a number of Gram-positive bacteria. We previously reported the heterologous production of D13E in Lactococcus lactis NZ9000 under the control of nisin-controlled gene expression system. In this study, we demonstrated enhanced production of D13E by the additional expression of immunity genes, nukFEG. The nukacin ISK-1 immunity, conferred by the ABC transporter complex, NukFEG, and the lantibiotic-binding protein, NukH, was not overwhelmed by D13E. The additional NukFEG resulted in a fourfold increase in the immunity level of the strain and a 5.2-fold increase in D13E production. The additional NukFEGH-expressing strain with the highest D13E immunity showed reduced level of production. Further improvement in D13E production was achieved by using pH-controlled batch fermentation.
Nukacin D13E (D13E) 是由金黄色葡萄球菌 ISK-1 产生的新型 A(II) 类细菌素 nukacin ISK-1 的变体。D13E 对多种革兰氏阳性菌的特定抗菌活性比 nukacin ISK-1 高两倍。我们之前曾报道过在乳酸乳球菌 NZ9000 中通过乳链菌肽控制基因表达系统异源生产 D13E。在这项研究中，我们通过表达额外的免疫基因 nukFEG 来证明 D13E 的产量增加。NukFEG 介导的 ABC 转运体复合物、NukH 和 nukacin ISK-1 的免疫作用不会被 D13E 所克服。额外的 NukFEG 使菌株的免疫水平提高了四倍，D13E 的产量提高了 5.2 倍。具有最高 D13E 免疫性的额外 NukFEGH 表达菌株的产量水平降低。通过使用 pH 控制分批发酵进一步提高了 D13E 的产量。
